Brainsway (NASDAQ:BWAY) Earns Buy Rating from HC Wainwright

Key Points

• HC Wainwright has reiterated a "buy" rating for Brainsway (NASDAQ:BWAY) with a target price of $17.00, indicating a potential upside of 11.84% from its previous close.
• Brainsway's stock has seen a significant increase in analyst ratings, with Wall Street Zen upgrading its rating from "hold" to "buy" and Northland Securities raising the target price from $15.00 to $19.00.
• The company reported better-than-expected quarterly earnings, with an EPS of $0.10, exceeding estimates of $0.07, and a revenue of $12.63 million surpassing analyst predictions.

Brainsway (NASDAQ:BWAY - Get Free Report)'s stock had its "buy" rating restated by HC Wainwright in a report issued on Monday,Benzinga reports. They currently have a $17.00 target price on the stock. HC Wainwright's target price points to a potential upside of 11.84% from the stock's previous close.

A number of other equities analysts have also commented on the stock. Wall Street Zen raised shares of Brainsway from a "hold" rating to a "buy" rating in a research report on Sunday, August 17th. Northland Securities raised their target price on shares of Brainsway from $15.00 to $19.00 and gave the stock an "outperform" rating in a research report on Thursday, August 14th. Two analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $18.00.

Brainsway Price Performance

Brainsway stock opened at $15.20 on Monday. Brainsway has a 1-year low of $7.06 and a 1-year high of $15.61. The firm has a market capitalization of $287.28 million, a P/E ratio of 58.46 and a beta of 1.42. The company's 50-day moving average is $12.43 and its 200 day moving average is $10.68.

Brainsway (NASDAQ:BWAY - Get Free Report) last posted its quarterly earnings data on Wednesday, August 13th. The company reported $0.10 earnings per share for the quarter, topping analysts' consensus estimates of $0.07 by $0.03. Brainsway had a net margin of 11.60% and a return on equity of 8.97%. The company had revenue of $12.63 million for the quarter, compared to analyst estimates of $12.34 million. Brainsway has set its FY 2025 guidance at EPS. Research analysts anticipate that Brainsway will post 0.08 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Brainsway

Several institutional investors have recently bought and sold shares of the company. Lazard Asset Management LLC acquired a new stake in shares of Brainsway during the fourth quarter worth $44,000. GAMMA Investing LLC lifted its stake in shares of Brainsway by 720.7% during the first quarter. GAMMA Investing LLC now owns 9,356 shares of the company's stock worth $89,000 after buying an additional 8,216 shares during the period. JPMorgan Chase & Co. lifted its stake in shares of Brainsway by 61.9% during the fourth quarter. JPMorgan Chase & Co. now owns 23,918 shares of the company's stock worth $226,000 after buying an additional 9,149 shares during the period. Two Sigma Investments LP lifted its stake in shares of Brainsway by 2.0% during the fourth quarter. Two Sigma Investments LP now owns 92,755 shares of the company's stock worth $875,000 after buying an additional 1,786 shares during the period. Finally, Two Sigma Advisers LP lifted its stake in shares of Brainsway by 32.6% during the fourth quarter. Two Sigma Advisers LP now owns 60,600 shares of the company's stock worth $571,000 after buying an additional 14,900 shares during the period. 30.11% of the stock is currently owned by institutional investors and hedge funds.

About Brainsway

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.